Study of Stapokibart Injection in Patients With Allergic Rhinitis

Inclusion Criteria: * Able to understand the study and voluntarily sign the Informed consent form. * Diagnosed Allergic Rhinitis according to the Criteria stated in the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, Revised Edition). * Subjects with asthma must be evaluated by the researcher as having a stable condition. * Has a positive skin prick test (SPT) or positive antigen-specific serum immunoglobulin E (IgE). Exclusion Criteria: * Use of anti-interleukin 4 receptor alpha subunit (IL-4Rα) monoclonal antibody, thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody, other monoclonal antibodies, or other biologics within 10 weeks or 5 half-lives (whichever is longer) prior to the screening visit. * Use of any investigational product within 4 weeks prior to the screening visit or planning to participate in other clinical studies during this study. * Forced expiratory volume in 1 second (FEV1) ≤ 50% of the predicted value during the screening/run-in period. * Have acute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening. * Have received a live-attenuated vaccine within 12 weeks prior to randomization or planning to receive one during the study.